# Phase I/II Study of DFP-10917 in Patients With Acute Leukemia

Source: https://onco.cc/trials/nct01702155/  
OnCo record `nct01702155` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of DFP-10917 run by Delta-Fly Pharma, Inc., completed.

## Summary

Phase I/II Study of DFP-10917 in Patients With Acute Leukemia is a phase 1/2 interventional study registered as NCT01702155 by Delta-Fly Pharma, Inc., with 69 participants enrolled, started 2012-10-10. Conditions recorded: Acute Myeloid Leukemia and Acute Lymphocytic Leukemia. Interventions recorded: DFP-10917.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01702155
- Phase: 1/2
- Setting: A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia
- Sponsor: Delta-Fly Pharma, Inc.
- Enrolled: 69

## Sources

- ClinicalTrials.gov NCT01702155: https://clinicaltrials.gov/study/NCT01702155

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [DFP-10917](https://onco.cc/drugs/dfp-10917/)
- companies: [Delta-Fly Pharma](https://onco.cc/companies/delta-fly-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct01702155.json